Telo Genomics Reports Additional Clinical Research Results Comparing Blood-Based TELO-MRD with Bone-Marrow Next-Generation Flow and Next-Generation Sequencing
Telo Genomics reported additional clinical research results showing blood-based TELO-MRD detected circulating plasma cells in every evaluable matched sample versus bone-marrow Adaptive clonoSEQ testing across Cleveland Clinic and Jewish General Hospital cohorts. In the previously reported EuroFlow NGF comparison, TELO-MRD detected myeloma cells in 39/42 matched samples (92.9%) versus 23/42 (54.8%) for bone-marrow flow cytometry, though the company cautions these are limited, preliminary datasets requiring confirmation in larger independent studies.
Key figures
- Drug Name
- TELO-MRD
- Phase Of Trial
- clinical research (matched comparison cohorts)
- Commercial target
- commercial application by end of calendar 2027
- Euroflow detection rate
- 54.8% (23/42)
- Euroflow matched samples
- 42
- Clonoseq matched comparisons
- 17
- Longitudinal mrd assessments
- 10
- Telo detection rate euroflow comparison
- 92.9% (39/42)
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.